NASDAQ:VRAY - Viewray Stock Price, Forecast & News

Viewray trades on the NASDAQ under the ticker symbol "VRAY."

Viewray Inc (NASDAQ:VRAY) announced its quarterly earnings data on Tuesday, November, 12th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.27) by $0.06. The company earned $20.90 million during the quarter, compared to analysts' expectations of $20.66 million. Viewray had a negative net margin of 110.61% and a negative return on equity of 75.41%. The business's quarterly revenue was up 18.1% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.39) EPS. View Viewray's Earnings History.

Viewray is scheduled to release their next quarterly earnings announcement on Thursday, March 12th 2020. View Earnings Estimates for Viewray.

Viewray will be holding an earnings conference call on Thursday, March 12th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Viewray updated its fourth quarter 2019 Pre-Market earnings guidance on Monday, January, 13th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $17-17 million, compared to the consensus revenue estimate of $18.27 million.

9 equities research analysts have issued 12-month target prices for Viewray's shares. Their forecasts range from $5.00 to $9.00. On average, they expect Viewray's stock price to reach $6.44 in the next twelve months. This suggests a possible upside of 106.6% from the stock's current price. View Analyst Price Targets for Viewray.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Viewray in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Viewray.

Media coverage about VRAY stock has trended somewhat positive this week, InfoTrie Sentiment Analysis reports. The research group rates the sentiment of news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Viewray earned a media sentiment score of 1.2 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for Viewray.

Some companies that are related to Viewray include Natus Medical (NTUS), AxoGen (AXGN), Zynex (ZYXI), Cutera (CUTR), Semler Scientific (SMLR), TransMedics Group (TMDX), BioLife Solutions (BLFS), Stereotaxis (STXS), Rockwell Medical (RMTI), Soleno Therapeutics (SLNO), Fonar (FONR), Edap Tms (EDAP), BioSig Technologies (BSGM), Second Sight Medical Products (EYES) and IRIDEX (IRIX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Viewray investors own include Alibaba Group (BABA), Amarin (AMRN), Sorrento Therapeutics (SRNE), Corbus Pharmaceuticals (CRBP), Pieris Pharmaceuticals (PIRS), T2 Biosystems (TTOO), Zynerba Pharmaceuticals (ZYNE), Advanced Micro Devices (AMD), Cara Therapeutics (CARA) and Amicus Therapeutics (FOLD).

(VRAY) raised $52 million in an initial public offering (IPO) on the week of April 6th 2015. The company issued 4,000,000 shares at $12.00-$14.00 per share. Cowen and Company and Stifel served as the underwriters for the IPO and BTIG and Brean Capital were co-managers.

Viewray's stock is owned by many different of retail and institutional investors. Top institutional investors include Fosun International Ltd (23.96%), FMR LLC (21.79%), Artisan Partners Limited Partnership (6.09%), Broadfin Capital LLC (5.61%), Bamco Inc. NY (2.00%) and State Street Corp (1.43%). Company insiders that own Viewray stock include Fmr Llc, International Ltd Fosun, James F Dempsey, Orbimed Advisors Llc, Scott William Drake and Shahriar Matin. View Institutional Ownership Trends for Viewray.

VRAY stock was sold by a variety of institutional investors in the last quarter, including Bank of America Corp DE, Barclays PLC, New York State Common Retirement Fund, UBS Asset Management Americas Inc., Artisan Partners Limited Partnership, Goldman Sachs Group Inc., Royce & Associates LP and Virtu Financial LLC. View Insider Buying and Selling for Viewray.

VRAY stock was purchased by a variety of institutional investors in the last quarter, including FMR LLC, Fosun International Ltd, Broadfin Capital LLC, Bamco Inc. NY, Marshall Wace North America L.P., Driehaus Capital Management LLC, Geode Capital Management LLC and Candriam Luxembourg S.C.A.. Company insiders that have bought Viewray stock in the last two years include International Ltd Fosun, Scott William Drake and Shahriar Matin. View Insider Buying and Selling for Viewray.

Shares of VRAY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of VRAY stock can currently be purchased for approximately $3.12.

Viewray has a market capitalization of $310.15 million and generates $80.96 million in revenue each year. The company earns $-76,400,000.00 in net income (profit) each year or ($0.98) on an earnings per share basis. View Additional Information About Viewray.

The official website for Viewray is http://www.viewray.com/.

Viewray's mailing address is 2 THERMO FISHER WAY, OAKWOOD VILLAGE OH, 44146. The company can be reached via phone at 440-703-3210 or via email at [email protected]